Madrigal Pharmaceuticals (MDGL:NYQ) stock is up 250% intraday on successful results from its Liver Disease trials. The company has been working on a late-stage clinical trial to treat liver disease, which prompted the surge in price. The company is off...
Vallon Pharmaceuticals (VLON:NYQ) and GRI BIO, Inc entered into a definitive agreement where Vallon will absorb GRI Bio in an all-stock transaction. The driver behind...
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has reported results from its biomarker study conducted to evaluate the potential CogniC, NeuroSense’s drug for treatment of Alzheimer’s disease....
Omnicom Group Inc. (NYSE: OMC) media services division Omnicom Media Group has partnered with Walmart Connect. Making the announcement at the Cannes Lions Festival of...
Hillstream BioPharma, Inc. (Nasdaq: HILS) today announced that it has begun a collaboration with Sapien Biosciences to evaluate the synergy of HSB-1216 with immune checkpoint...
F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that invoX Pharma, subsidiary of Sino Biopharm has plans to acquire the company for USD 7.12 per share. ...
uniQure N.V. (NASDAQ: QURE) share up more than 15% after the Company announced on Thursday new safety and biomarker data from 10 patients enrolled in...
Day One Biopharmaceuticals (Nasdaq: DAWN) today announced positive initial data from pivotal FIREFLY-1 trial of Tovorafenib. Shares of Day One Biopharmaceuticals (Nasdaq: DAWN) opened 125%...
Cogent Biosciences, Inc. (NASDAQ: COGT) is up more than 60% after the Company announced positive initial data from its ongoing Phase 2 APEX clinical trial...
Moderna, Inc. (NSDAQ: MRNA) has reported new clinical data on Omicron bivalent COVID booster candidate, MRNA-1273.214 and a vaccine candidate targeting the Omicron variant in...
JanOne Inc. (NASDAQ: JAN) shares spike more than 50% on Tuesday after the company announced that a patent was issued that covers a method of...
Yumanity Therapeutics, Inc. (Nasdaq: YMTX) today announced that it has entered into definitive agreements for two strategic transactions. Up Over 46% Shares of Yumanity Therapeutics,...
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has reported results from a Phase 2/3 Aria Study that evaluated the efficacy and safety of PRAX-114 for monotherapy...
